Understanding how the cellular environment impacts drug-stimulated signaling
Our research investigates how endogenous cellular components, including phospholipids and cholesterol, modulate the responses of receptor proteins to drugs. By elucidating these mechanisms, we aim to reveal how alterations in cellular conditions arising from metabolic changes, genetic variation, or disease affect individual responses to therapeutic treatments.
Discovering structural mechanisms underlying the pharmacology of G protein-coupled receptors (GPCRs)
GPCRs are membrane sensory proteins and the largest family of druggable targets, which include receptors for dopamine, serotonin, cannabinoids, opioids, and numerous hormones. More than one-third of all FDA-approved drugs act on human GPCRs. Our research seeks to uncover how endogenous and synthetic molecules modulate GPCR activity, with the ultimate goal of designing small molecules with enhanced therapeutic potential.
Engineering biologics with improved and predictable properties
Biologics are protein-based drugs that offer unique therapeutic potential but often lose effectiveness in the challenging environment of the human body. We use biophysical tools to investigate how polymer conjugation can enhance their stability and performance, with the goal of designing biologics that remain robust and effective in physiological conditions.